Brief: Zentalis Pharmaceuticals Provides Corporate Update
06/01/2026 13:59
Jan 6 (Reuters) - Zentalis Pharmaceuticals Inc ZNTL.O: ZENTALIS PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS KEY MILESTONES AND EXPECTED MOMENTUM IN THE AZENOSERTIB DEVELOPMENT PROGRAM FOR 2026 ZENTALIS PHARMACEUTICALS INC - DENALI PART 2 TOPLINE READOUT EXPECTED BY YEAR END 2026 ZENTALIS PHARMACEUTICALS INC - ASPENOVA PHASE 3 TRIAL INITIATION PLANNED IN 1H 2026 ZENTALIS PHARMACEUTICALS INC - DENALI PART 2A ENROLLMENT COMPLETED; DOSE CONFIRMATION EXPECTED 1H 2026 Source text: ID:nGNX1FHn43 Further company coverage: ZNTL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer